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Background: The aim was to establish the features of metabolic disorders and the state 
of the renin–angiotensin–aldosterone system (RAAS) in obese patients with true and 
pseudo–resistant arterial hypertension (AH). 
Material and Methods: The study included 200 patients with uncontrolled AH and obesity. 
Patients were initially prescribed dual antihypertensive therapy. Those patients who did 
not reach target blood pressure (BP) levels after 3 months on dual therapy were 
additionally assigned a third antihypertensive drug. Of the 98 patients who were assigned 
triple therapy, 48 patients did not reach target BP (27 patients had pseudo–resistant and 
21 patients had true resistant AH). These patients were additionally prescribed a fourth 
antihypertensive drug (spironolactone). The effectiveness of the treatment was evaluated 
6 months after the start of antihypertensive therapy. 
Results: After 6 months of therapy, unlike patients without resistance, individuals with 
resistant AH differed more pronounced metabolic disorders and higher activity of the 
RAAS. Patients with true resistance differed from pseudo–resistant patients with 
significantly lower body mass index (BMI); in the absence of differences in BP levels, lipid 
and carbohydrate profiles, patients with true resistance had significantly higher levels of 
aldosterone, higher adiponectin levels, and lower leptin level. 
Conclusions: Obese patients with true resistance differed from pseudo–resistant patients 
with significantly lower BMI, higher aldosterone levels, and less pronounced adipokines 
imbalance. 
 
